- Home
- DBVT vs MXCT Comparison
DBVT vs MXCT Comparison
Compare DBVT & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBVT
- MXCT
- Stock Information
- Founded
- DBVT 2002
- MXCT 1999
- Country
- DBVT France
- MXCT United States
- Employees
- DBVT N/A
- MXCT N/A
- Industry
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- MXCT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- DBVT Health Care
- MXCT Health Care
- Exchange
- DBVT Nasdaq
- MXCT Nasdaq
- Market Cap
- DBVT 273.6M
- MXCT 242.4M
- IPO Year
- DBVT N/A
- MXCT 2021
- Fundamental
- Price
- DBVT $9.66
- MXCT $1.40
- Analyst Decision
- DBVT Buy
- MXCT Buy
- Analyst Count
- DBVT 4
- MXCT 4
- Target Price
- DBVT $14.81
- MXCT $7.50
- AVG Volume (30 Days)
- DBVT 35.5K
- MXCT 1.2M
- Earning Date
- DBVT 07-29-2025
- MXCT 08-06-2025
- Dividend Yield
- DBVT N/A
- MXCT N/A
- EPS Growth
- DBVT N/A
- MXCT N/A
- EPS
- DBVT N/A
- MXCT N/A
- Revenue
- DBVT $3,800,000.00
- MXCT $35,754,000.00
- Revenue This Year
- DBVT $1,743.46
- MXCT N/A
- Revenue Next Year
- DBVT $1,045.66
- MXCT $14.79
- P/E Ratio
- DBVT N/A
- MXCT N/A
- Revenue Growth
- DBVT N/A
- MXCT N/A
- 52 Week Low
- DBVT $2.21
- MXCT $1.26
- 52 Week High
- DBVT $12.78
- MXCT $5.20
- Technical
- Relative Strength Index (RSI)
- DBVT 49.63
- MXCT 31.00
- Support Level
- DBVT $8.91
- MXCT $1.37
- Resistance Level
- DBVT $10.34
- MXCT $1.48
- Average True Range (ATR)
- DBVT 0.54
- MXCT 0.09
- MACD
- DBVT -0.03
- MXCT 0.02
- Stochastic Oscillator
- DBVT 52.61
- MXCT 46.43
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
About MXCT MaxCyte Inc.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.